Inogen (NASDAQ:INGN) reached a new 52-week high and low on Monday . The company traded as low as $144.31 and last traded at $142.33, with a volume of 25560 shares changing hands. The stock had previously closed at $141.08.
INGN has been the topic of a number of recent research reports. Zacks Investment Research downgraded Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $150.00 price objective on shares of Inogen in a report on Tuesday, March 27th. Piper Jaffray set a $145.00 price objective on Inogen and gave the company a “buy” rating in a report on Saturday, April 14th. BidaskClub downgraded Inogen from a “buy” rating to a “hold” rating in a report on Friday, March 2nd. Finally, ValuEngine raised Inogen from a “hold” rating to a “buy” rating in a report on Friday, April 6th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $121.17.
The firm has a market cap of $2,992.84, a price-to-earnings ratio of 108.60, a P/E/G ratio of 3.93 and a beta of 1.03.
Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, February 27th. The medical technology company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. The company had revenue of $63.79 million for the quarter, compared to the consensus estimate of $62.01 million. Inogen had a return on equity of 13.47% and a net margin of 8.42%. equities analysts forecast that Inogen will post 1.6 EPS for the current fiscal year.
In other news, CFO Alison Bauerlein sold 11,718 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $115.87, for a total value of $1,357,764.66. Following the transaction, the chief financial officer now directly owns 11,718 shares of the company’s stock, valued at approximately $1,357,764.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brenton Taylor sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $117.47, for a total value of $1,762,050.00. Following the completion of the transaction, the executive vice president now directly owns 38,982 shares in the company, valued at $4,579,215.54. The disclosure for this sale can be found here. Insiders sold a total of 115,718 shares of company stock worth $14,059,611 over the last three months. 5.29% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Inogen by 4.0% in the 4th quarter. BlackRock Inc. now owns 2,306,534 shares of the medical technology company’s stock worth $274,662,000 after acquiring an additional 87,737 shares in the last quarter. Brown Capital Management LLC boosted its holdings in shares of Inogen by 1.8% in the 4th quarter. Brown Capital Management LLC now owns 2,260,706 shares of the medical technology company’s stock worth $269,205,000 after acquiring an additional 40,994 shares in the last quarter. Rockefeller Financial Services Inc. boosted its holdings in shares of Inogen by 0.9% in the 4th quarter. Rockefeller Financial Services Inc. now owns 301,499 shares of the medical technology company’s stock worth $35,903,000 after acquiring an additional 2,729 shares in the last quarter. Fred Alger Management Inc. boosted its holdings in shares of Inogen by 7.9% in the 4th quarter. Fred Alger Management Inc. now owns 248,232 shares of the medical technology company’s stock worth $29,559,000 after acquiring an additional 18,269 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Inogen by 27.3% in the 4th quarter. Renaissance Technologies LLC now owns 198,736 shares of the medical technology company’s stock worth $23,665,000 after acquiring an additional 42,636 shares in the last quarter. 98.87% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Inogen (INGN) Sets New 1-Year High and Low at $144.31” was originally reported by Macon Daily and is owned by of Macon Daily. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://macondaily.com/2018/04/23/inogen-ingn-sets-new-1-year-high-and-low-at-144-31.html.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.